Issue #46

Issue #46

April 13, 2023

April 13, 2023 | Issue #46

Good evening. Welcome back to another issue of Spannr.In this week's newsletter:đŸ’„ Blood in the streets?📖 Pubco overviews (new feature)📚 Good reads from around the web

Revisiting The Index...

In May 2022, nearly one year ago, Spannr launched the first-ever stock index to track US-listed, publicly-traded companies that are explicitly focused on aging or aim to extend healthy human lifespans.The Index launched with a base price of $100 and, in less than 45 days, soared ~45% to $145.85 on August 15, 2022.Since peaking in August, however, the Index has been steadily losing value – with the index dropping below its base price of $100 as recently as last week.So what gives?Is the public longevity industry struggling? Or, is it just the market impacting all of biotech?Well, a little bit of both.The past 12 months have been absolutely brutal for investors
 regardless of the sector.But some of the stocks in the index aren’t doing their investors (or the index) any favors. Unity Biotechnology (UBX), for example, failed its Phase 2 trial recently, leading to the stock losing more than 60% of its value.What’s Next?For now, the chaos has settled, with the index slightly back above its base price of $100. And although investors (biotech investors, in particular) remain on alert for another shoe to drop, any sign of positive market sentiment (disinflation, Fed pivot, etc.) could lead to positive performance for longevity biotech companies.Although the Spannr Longevity Index takes an agnostic view on individual companies (unlike Spannr Ventures) and lists all Pubco’s doing work in longevity, we aim to provide the most informative and potentially alpha-generating information on the market to longevity investors.So, while the market is down and there is “blood in the streets” as they say, we thought it would be useful to highlight some of the research our team has been providing on individual companies.Within the past few months, we've been quietly building out company profiles to explain in greater detail what each Pubco in the space is attacking.Of all our company profiles, here are the most recent:

  • Tenaya Therapeutics (TNYA)Market Cap: $201.6 MillionWhat They Do: Tenaya is a biotechnology company focused on developing therapies that address the underlying drivers of heart disease.

  • Invitae(NVTA)Market Cap: $374.9 MillionWhat They Do: Invitae is a biotechnology company that aims to improve healthcare by making genetic testing part of mainstream medical practice.

  • Chromadex(CDXC)Market Cap: $110.0 MillionWhat They Do: ChromaDex is a global bioscience and dietary supplement company that is focused on promoting healthy aging by raising nicotinamide adenine dinucleotide (NAD+) levels in the body.

  • Humacyte(HUMA)Market Cap: $342.0 MillionWhat They Do: Humacyte is a biotechnology company that develops and manufactures universally implantable, bio-engineered human tissues that are ready for off-the-shelf application to treat a range of diseases and conditions.

You can view the profiles of all public longevity companies that our index is comprised of 

.

You can

also

read our guide on how to evaluate longevity stocks 

.

And lastly, as a reminder, each week we provide an "Index Snapshot" (shown at the bottom of this letter 👇) so readers can stay up to date on performance.

  • The rich are pouring millions into life extension research – but does it have any ethical value? (The Conversation)

  • Longevity for companion animals: why should we care (Stanete)

  • Humans Can Stop—But Not Fully Reverse—Aging, Study Suggests (Popular Mechanics)

  • 1st Quarter Longevity Investment Report (Longevity.Technology)

  • America’s decline in life expectancy speaks volumes about our problems (LA Times)

  • Here's what experts say to eat to expand your lifespan, from pomegranates to red onions (Inside)

  • Stem Cell ‘Junk Yards’ Reveal a New Clue About Aging (Wired)

  • Rapamycin, the only drug that has been consistently demonstrated to increase mammalian longevity. An update (Science Direct)

Performance:

Latest Price: $103.067d-Return: 2.62%Market Cap: $10.56b

Big Movers:Miromatrix (MIRO): -14.84%SomaLogic (SLGC): 12.45%Tenaya (TNYA): 13.53%

ABOUT SPANNR

We are dedicated to helping people understand the biggest business and health story of all time: the unprecedented transformation of society that will result from extending human healthspan and lifespan.

If you have any questions about Spannr or want to get to know us better, 

 â€“ we'd love to hear from you. We appreciate your interest in what we are creating.